Skip to content

ASCO 2022 Annual Meeting

Experts from the Mass General Cancer Center will present groundbreaking cancer research at this year’s ASCO 2022 Annual Meeting, held June 3 – 7, 2022, both in-person in Chicago, IL, and virtually.

This year’s ASCO 2022 Annual Meeting will be held June 3 – 7, 2022, both in-person in Chicago, IL, and virtually. Over 40,000 oncology professionals from around the world will attend this prestigious event, which provides updates on new clinical advances in every area of cancer research and strives to advance equitable cancer care through international innovation.

See the full program »

The Mass General Cancer Center will have a strong presence at this event, with dozens of leaders sharing their latest research in abstract presentations, poster sessions, discussions and more.

Friday, June 3, 2022


Lipika Goyal, MD

5:30 pm: Abstract Presentation
Updated Results of the FOENIX-CCA2 Trial: Efficacy and Safety of Futibatinib in Intrahepatic Cholangiocarcinoma (iCCA) Harboring FGFR2 Fusions/Rearrangements.

Colin D. Weekes, MD, PhD

6:06 pm: Abstract Presentation
Can We Predict Responders to Treatment in Patients With Pancreas Cancer?

Saturday, June 4, 2022

Rachel Jimenez, MD

2:15 pm: Poster Session
Oncologists’ Perspectives on Individualizing Dose Selection for Patients With Metastatic Cancer.

Daniel Lage, MD

2:15 pm: Poster Session
CONTINUUM: A Pilot Care Transition Intervention for Hospitalized Patients With Advanced Cancer.

Richard T. Penson, MD, MRCP

2:15 pm: Poster Session
Pivotal Study of Ofra-vec (VB-111) Combined With Paclitaxel Versus Paclitaxel for Treatment of Platinum-resistant Ovarian Cancer (OVAL, VB-111-701/GOG-3018).

Debra Lundquist, PhD, RN

2:15 pm: Poster Session
Patient-reported Hope, Quality of Life (QOL), Symptom Burden, and Coping Mechanisms in Early Phase Clinical Trial Participants.

Kelly Hsu, BA

2:15 pm: Poster Session
Optimizing Supportive Care for Patients With Metastatic Lung Cancer in the Era of Precision Oncology.

Sophia C. Kamran, MD

2:15 pm: Poster Session
Recent Trends of “Manels” and Gender Representation Among Panelists at the ASCO Annual Meeting.

Dejan Juric, MD

3:51 pm: Abstract Presentation
Alpelisib (ALP) + Fulvestrant (FUL) in Patients (pts) With Hormone Receptor–positive (HR+), Human Epidermal Growth Factor Receptor 2–negative (HER2−) Advanced Breast Cancer (ABC): Biomarker (BM) Analyses by Next-generation Sequencing (NGS) From the SOLAR-1 Study.

Ryan J. Sullivan, MD

4:00 pm: Presentation
Vaccines in Melanoma: A Promising Road Ahead

Steven Michael Blum, MD

4:27 pm: Oral Abstract Session
Single-cell Profiling of Human Heart and Blood in Immune Checkpoint Inhibitor-associated Myocarditis.

Elyse R. Park, PhD, MPH

4:39 pm: Abstract Presentation
A Health Insurance Navigation Intervention Tool (HINT) for Survivors of Childhood Cancer: Randomized Pilot Trial Results From the Childhood Cancer Survivor Study.

Andrew J. Yee, MD

5:30 pm: Poster Discussion Session
A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma.

Areej R. El-Jawahri, MD

5:30 pm: Poster Discussion Session
Psychological Mobile App for Patients With Acute Myeloid Leukemia (AML): A Randomized Clinical Trial.

Kimberly Klinger, MD

5:30 pm: Poster Discussion Session
Time to Biopsy of Screening Mammography-detected Abnormalities: Evaluating the Impact of Same-day Services Implemented During the COVID-19 Pandemic.

Aparna Raj Parikh, MD

5:52 pm: Discussion
Becoming a Global Citizen of Oncology.

Sunday, June 5, 2022

Ina Ly, MBBS

9:00 am: Poster Session
Phase 2 Trial of Bavituximab With Chemoradiation and Adjuvant Temozolomide in Newly Diagnosed Glioblastoma.

Sara I. Pai, MD, PhD

9:00 am: Poster Session
A Phase II Study of Pembrolizumab for HPV-associated Papilloma Patients With Laryngeal, Tracheal, and/or Pulmonary Involvement.

Gregory Michael Cote, MD, PhD

9:00 am: Poster Session
A Phase 1b Lead-in to a Randomized Phase 2 Trial of Lurbinectedin Plus Doxorubicin in Leiomyosarcoma (LMS).

Matthew J. Frigault, MD

10:00 am: Abstract Presentation
Phase 1 Study of CART-ddBCMA in Relapsed or Refractory Multiple Myeloma.

Melissa Gardner, MA

12:30 pm: Poster Discussion Session
A Controlled Comparison of Cerebral Volume Loss After Brain Irradiation With Proton Versus Photon Radiotherapy.

Monday, June 6, 2022

Sophia C. Kamran, MD

9:00 am: Discussion
Two Steps Forward, One Step Back: How Can We Achieve Gender Equity of Scientific Presentations at ASCO?

Aditya Bardia, MD, FASCO, MPH

9:00 am: Poster Session
Sacituzumab Govitecan (SG) Versus Treatment of Physician’s Choice (TPC) in Patients (pts) With Previously Treated, Metastatic Triple-negative Breast Cancer (mTNBC): Final Results From the Phase 3 ASCENT Study.

Anurag Saraf, MD

9:00 am: Poster Session
Low Skeletal Muscle Area and Association With Toxicity and Hospitalization With Chemotherapy in Advanced Non–small Cell Lung Cancer.

Catherine Belle Meador, MD, PhD

9:00 am: Poster Session
Phase I/II Investigator-initiated Study of Olaparib and Temozolomide in SCLC: Updated Analysis and CNS Outcomes.

Dejan Juric, MD

1:04 pm: Poster Discussion
Alpelisib (ALP) + Endocrine Therapy (ET) in Patients (pts) With Hormone Receptor-positive (HR+), Human Epidermal Growth Factor Receptor 2-negative (HER2–), PIK3CA-mutated (mut) Advanced Breast Cancer (ABC): Baseline Biomarker Analysis and Progression-free Survival (PFS) by Duration of Prior Cyclin-dependent Kinase 4/6 Inhibitor (CDK4/6i) Therapy in the BYLieve Study.

Kanhua Yin, MD, MPH

2:15 pm: Poster Session
Mainstreamed Genetic Testing of Patients With Breast Cancer: Experience From a Single Surgeon’s Practice in a Large U.S. Academic Center.

Sophia Z. Shalhout, PhD

2:15 pm: Poster Session
A Retrospective Study of Ipilimumab Plus Nivolumab in Anti–PD-L1/PD-1-refractory Merkel Cell Carcinoma.

Ryan J. Sullivan, MD

2:15 pm: Poster Session
Treatment With Tebentafusp Beyond Radiographic Progressive Disease (PD) in Metastatic Uveal Melanoma (mUM).

Lipika Goyal, MD

2:15 pm: Poster Session
Design and Rationale of a First-in-Human (FIH) Phase 1/1b Study Evaluating KIN-3248, a Next-generation, Irreversible (irrev), Pan-FGFR Inhibitor (FGFRi), in Adult Patients With Solid Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations (NCT05242822).

Sienna Durbin, MD

2:15 pm: Poster Session
Relationship of Travel Distance With Patient Demographics, Advance Care Planning, and Survival in Early-phase Clinical Trials (EP-CTs).

Joy X. Jarnagin, BA

2:15 pm: Poster Session
Changes in Functional Assessment of Cancer Therapy: General (FACT-G) to Predict Treatment Response and Survival Outcomes in Patients With Metastatic Gastrointestinal (GI) Cancer.

Laura Spring, MD

2:27 pm: Poster Discussion
Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-negative Breast Cancer: Results From the NeoSTAR Trial.

Ibiayi Dagogo-Jack, MD

2:37 pm: Discussion
Lung Trek: The Next Frontier of Therapies.

Helen Alice Shih, MD, MS, MPH

3:06 pm: Discussion
Genome and Beyond in Central Nervous System Malignancies.

Priscilla Kaliopi Brastianos, MD

4:00 pm: Presentation
Molecular Drivers in the Evolution of Brain Metastases and Implications on Treatment.

Beverly Moy, MD, FASCO, MPH

5:30 pm: Discussion
Trials and Tribulations: Disparities in Clinical Trial Access, Participation, and Outcomes.

Seth Andrew Wander, MD, PhD

6:06 pm: Abstract Presentation
Use of Real-world Data (RWD) to Assess the Utility of Cell-free Circulating Tumor DNA (cfDNA) in Identifying Resistance to Early Treatment in Advanced Breast Cancer (aBC).

Tuesday, June 7, 2022

Gabriela Hobbs, MD

12:09 pm: Discussion
MPNs: Play Your Targets Right.